Subscribe to RSS
DOI: 10.1055/s-0035-1545945
Combined Therapy with Rheum tanguticum Polysaccharide and Low-dose 5-ASA Ameliorates TNBS-Induced Colitis in Rats by Suppression of NF-κB
Publication History
received 21 July 2014
revised 15 November 2014
accepted 24 March 2015
Publication Date:
12 June 2015 (online)
![](https://www.thieme-connect.de/media/plantamedica/201509/lookinside/thumbnails/10-1055-s-0035-1545945_pmy1265-1.jpg)
Abstract
The most common conventional therapy for inflammatory bowel disease in clinical practice involves the use of nonsteroidal anti-inflammatory drugs, such as 5-amino salicylic acid. However, a high dose of 5-amino salicylic acid may bring about severe side effects. Chinese people have used Rheum tanguticum as a folk remedy for gastrointestinal disease for two thousand years. Our group has isolated R. tanguticum polysaccharide 1 from R. tanguticum and verified that it can attenuate 2,4,6-trinitrobenzene sulfonic acid-induced colitis in murines/rats. The present study aims to evaluate whether the addition of R. tanguticum polysaccharide 1 can improve efficacy and limit subsequent side effects of conventional treatment (5-amino salicylic acid) in rats with 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Sixty Sprague-Dawley male rats were randomized into five groups and treated with (1) saline (saline, 0.2 mL/day × 5, p. o.), (2) 2,4,6-trinitrobenzene sulfonic acid alone (saline, 0.2 mL/day × 5, p. o.), (3) 2,4,6-trinitrobenzene sulfonic acid + 5-amino salicylic acid (5-amino salicylic acid, 75 mg/kg/day × 5, p.o), (4) 2,4,6-trinitrobenzene sulfonic acid + R. tanguticum polysaccharide 1 (R. tanguticum polysaccharide 1, 200 mg/kg/day × 5, p. o.), and (5) 2,4,6-trinitrobenzene sulfonic acid + 5-amino salicylic acid + R. tanguticum polysaccharide 1 (5-amino salicylic acid, 25 mg/kg/day × 5, p.o; R. tanguticum polysaccharide 1, 200 mg/kg/day × 5, p. o.). All the rats were sacrificed on the 6th day after treatment using an overdose of anesthesia. A histological assessment was performed using semiquantitative scores; nuclear factor-kappa B and tumor necrosis factor-α were measured with Western blot, cyclooxygenase 1 and cyclooxygenase 2 protein expressions were investigated by RT-polymerase chain reaction, and prostoglandin E2 and inducible nitric oxide synthase productions were investigated by ELISA. The extent and severity of histological signs were attenuated significantly in the 2,4,6-trinitrobenzene sulfonic acid + 5-amino salicylic acid + R. tanguticum polysaccharide 1 group. Treatment with R. tanguticum polysaccharide 1 plus 5-amino salicylic acid markedly decreased nuclear factor-kappa Bp65 and tumor necrosis factor-α protein expressions. R. tanguticum polysaccharide 1 and 5-amino salicylic acid had no effect on cyclooxygenase 1 protein expression, but inhibited the overexpression of the cyclooxygenase 2 protein. After treatment with 5-amino salicylic acid and R. tanguticum polysaccharide 1, the prostoglandin E2 level increased significantly and the inducible nitric oxide synthase level decreased considerably in the 2,4,6-trinitrobenzene sulfonic acid + 5-amino salicylic acid + R. tanguticum polysaccharide 1 group compared with the 2,4,6-trinitrobenzene sulfonic acid alone group. These results demonstrate that combined therapy with R. tanguticum polysaccharide 1 and low-dose 5-amino salicylic acid had more favorable effects on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats, and its effects may be associated with inhibiting nuclear factor-kappa Bp65 protein expression and tumor necrosis factor-α production, resulting in a decrease of cyclooxygenase 2 and inducible nitric oxide synthase protein expressions.
Key words
combined therapy - 5-ASA - Rheum tanguticum polysaccharide - Polygonaceae - NF-κB suppressing - TNF-α inhibition* These two authors contributed equally to this work.
-
References
- 1 Cho EJ, Shin JS, Noh YS, Cho YW, Hong SJ, Park JH, Lee JY, Lee KT. Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis. J Ethnopharmacol 2011; 136: 428-435
- 2 da Silva MS, Sanchez-Fidalgo S, Talero E, Cardeno A, da Silva MA, Villegas W, Souza Brito AR, de La Lastra CA. Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol 2010; 128: 467-475
- 3 de Almeida AB, Sanchez-Hidalgo M, Martin AR, Luiz-Ferreira A, Trigo JR, Vilegas W, dos Santos LC, Souza-Brito AR, de la Lastra CA. Anti-inflammatory intestinal activity of Arctium lappa L. (Asteraceae) in TNBS colitis model. J Ethnopharmacol 2013; 146: 300-310
- 4 de Faria FM, Luiz-Ferreira A, Socca EA, de Almeida AC, Dunder RJ, Manzo LP, da Silva MA, Vilegas W, Rozza AL, Pellizzon CH, Dos Santos LC, Souza Brito AR. Effects of Rhizophora mangle on Experimental Colitis Induced by TNBS in Rats. Evid Based Complement Alternat Med 2012; 2012: 753971
- 5 Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-1367
- 6 Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 2007; 320: 22-28
- 7 Liu L, Guo Z, Lv Z, Sun Y, Cao W, Zhang R, Liu Z, Li C, Cao S, Mei Q. The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. Int Immunopharmacol 2008; 8: 1481-1492
- 8 Liu L, Mei QB, Wang ZP, Zhou YM, Zhang H, Long Y, Liu JY. The Effects of Rheum Tanguticum Polysaccharide on the Polarization of Th1 and Th2 Cells in TNBS-Induced Colitis in Murine. Int J Biomed Sci 2005; 1: 23-32
- 9 Liu LN, Mei QB, Liu L, Zhang F, Liu ZG, Wang ZP, Wang RT. Protective effects of Rheum tanguticum polysaccharide against hydrogen peroxide-induced intestinal epithelial cell injury. World J Gastroenterol 2005; 11: 1503-1507
- 10 Mbodji K, Charpentier C, Guerin C, Querec C, Bole-Feysot C, Aziz M, Savoye G, Dechelotte P, Marion-Letellier R. Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-kappaB in rats with TNBS-induced colitis. J Nutr Biochem 2013; 24: 700-705
- 11 Motavallian A, Minaiyan M, Rabbani M, Mahzouni P, Andalib S, Abed A, Babavalian MR. Does Cisapride, as a 5HT(4) Receptor Agonist, Aggravate the Severity of TNBS-Induced Colitis in Rat?. Gastroenterol Res Pract 2012; 2012: 362536
- 12 Moussa L, Bezirard V, Salvador-Cartier C, Bacquie V, Lencina C, Leveque M, Braniste V, Menard S, Theodorou V, Houdeau E. A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease. PLoS One 2012; 7: e49547
- 13 Nagib MM, Tadros MG, ElSayed MI, Khalifa AE. Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. Toxicol Appl Pharmacol 2013; 271: 106-113
- 14 Nishitani Y, Zhang L, Yoshida M, Azuma T, Kanazawa K, Hashimoto T, Mizuno M. Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLoS One 2013; 8: e62441
- 15 Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008; 263: 597-606
- 16 Park KT, Perez F, Tsai R, Honkanen A, Bass D, Garber A. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2011; 53: 489-496
- 17 Park YS. [COX-2 inhibitors in inflammatory bowel disease: friends or foes?]. Korean J Gastroenterol 2007; 50: 350-355
- 18 Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012; 27: 1266-1280
- 19 Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011; 412: 671-687
- 20 Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 2007; 56: 2608-2619
- 21 Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23–>IL-17 axis. J Immunol 2007; 178: 8138-8147
- 22 Stack E, DuBois RN. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 2001; 30: 1001-1010
- 23 Dedeepiya V, Terunuma H, Manjunath S, Senthilkumar R, Thamaraikannan P, Srinivasan T, HelenReena C, Preethy S, Abraham S. Autologous Immune Enhancement Therapy for cancer using NK cells and CTLs without feeder layers; our six year experience in India. J Stem Cells Regen Med 2011; 7: 95
- 24 Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788
- 25 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434
- 26 Ye L, Cao Q, Cheng J. Review of inflammatory bowel disease in China. ScientificWorldJournal 2013; 2013: 296470